Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

December 22, 2016

Conditions
Crohn's Disease
Interventions
DRUG

Andecaliximab

Andecaliximab administered via subcutaneous (SC) injection

DRUG

Placebo

Placebo to match andecaliximab administered via SC injection

Trial Locations (74)

Unknown

Digestive Health Specialists of The Southeast, Dothan

Mayo Clinic, Scottsdale

Cedars Sinai Medical Center, Los Angeles

South Denver Gastroenterology, Lone Tree

University of Miami, Miami

Gastroenterology Group Of Naples, Naples

Gastroenterology Associates Of Central Georgia, LLC, Macon

Medical Diagnostic Center (MDC)-Indiana University (IU) Health University Hospital, Indianapolis

Iowa Digestive Disease Center, Clive

Cotton-O'Neil Clinical Research Center, Digestive Health, Topeka

Delta Research Partners, Monroe

Louisiana Research Center, Shreveport

University of Michigan, Ann Arbor

Clinical Research Institute of Michigan, LLC, Chesterfield

Mayo Clinic Rochester, Rochester

Washington University School of Medicine, St Louis

Dartmouth-Hitchcock Medical Center, Lebanon

AGA Clinical Research Associates, LLC, Egg Harbor

Columbia University Medical Center/ New York Presbyterian, New York

Premier Medical Group Of The Hudson Valley, Poughkeepsie

Mayo Clinic Rochester, Rochester

Asheville Gastroenterology Associates, Asheville

Consultants For Clinical Research, Cincinnati

Great Lakes Gastroenterology, Mentor

Gastro One, Germantown

Vanderbilt University Medical Center, Nashville

Texas Clinical Research Institute, Arlington

Ertan Digestive Disease Center of Excellence, UTH/MH-TMC, Houston

Gastroenterology Research of San Antonio, San Antonio

Gastroenterology Associates Of Tidewater, Chesapeake

Digestive and Liver Disease Specialists, Norfolk

Mcguire Dvamc, Richmond

University of Washington Medical Center, Seattle

Concord Repatriation General Hospital, Concord

Royal Adelaide Hospital, Adelaide

Flinders Medical Centre, Bedford Park

Footscray Hospital, Footscray

Gastroenterology/Colorectal Medicine & Genetics, Melbourne

Percuro Clinical Research Ltd., Victoria

Percuro Clinical Research Ltd., Victoria

Hepato-Gastroenterologie Hk S.R.O., Hradec Králové

Ibd Clinical And Research Centre-Iscare Ivf, Prague

Hopital Beaujon, Clichy

CHRU de Lille, Lille

Chu Hotel Dieu-Chu De Nantes, Nantes

CHU de Saint Etienne - Hopital Nord, Saint-Priest-en-Jarez

Universitatsklinikum Schleswig-Holstein, Kiel

Eugastro Gmbh, Leipzig

Klinikum der Universitat Munchen, München

Tolna Megye Balassa Janos Korhaz, Beri Balogh Adam

Rethy Pal Hospital-Clinic Bekescsaba, Békéscsaba

Pannonia Maganorvosi Centrum Kft, Budapest

Debreceni Egyeterm Orvos es Egeszsegtudomanyi Centrum, Debrecen

Universita Campus Biomedico, Roma

Humanitas Research Hospital, Rozzano

Christchurch Hospital, Christchurch

Southern District Health Board, Dunedin

Capital and Coast District Health board-Wellington hospital, Wellington

The Medical University of Bialystok Clinical, Bialystok

Gastromed, Lublin

Ai Centrum Medyczne, Poznan

CRC Sp. z o.o., Poznan

Endoskopia SP. z.o.o., Sopot

Centralny Szpital Kliniczny MSWiA, Warsaw

Lexmedica, Wroclaw

Panorama Mediclinic Pvt Hospital, Panorama

Parklands Medical Centre, Durban

Hospital Universitari de Bellvitge, Barcelona

Hospital Universitario de Fuenlabrada, Fuenlabrada

Hospital Ramon y Cajal, Madrid

Hospital Universitari i Politecnic La Fe de Valencia, Valencia

Norfolk and Norwich University Hospital Nhs Foundation Trust, Norwich

Cambridge University Hospitals NHS Foundation Trust, Cambridge

Oxford University Hospitals NHS Trust, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY